image credit- shutterstock
Thermo Fisher Scientific Inc., the world leader in serving science, will invest an additional $2 billion in the United States (US) over the next four years, strengthening American innovation, manufacturing and economic competitiveness across the life sciences sector.
As one of the largest manufacturers of medicines in the world, Thermo Fisher enables biopharma companies to develop and produce their medicines in America. These additional investments to the company’s American manufacturing capacity support a resilient US healthcare supply chain and will have a strong multiplier effect across the American economy.
The $2 billion investment over the next four years includes $1.5 billion in capital expenditures to enhance and expand US manufacturing operations; complemented by $500 million in R&D focused on high-impact innovation.
This investment builds on Thermo Fisher’s industry-leading foundation in US manufacturing and innovation. The company has 64 US manufacturing operations, located in 37 states, making analytical instruments, specialty diagnostics and life sciences solutions, as well as providing contract development and manufacturing services for pharmaceutical innovators.
Over the next four years, the company will continue to expand its impact in the US by creating high-paying jobs, adding manufacturing and lab services capacity, and investing in research and development.
